Liu Fei, Zhang Hongxia, Xue Lihua, Yang Qiankun, Yan Wanchun
Department of Nephrology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730000, P.R. China.
Department of Emergency Medicine, The First Hospital of The Chinese People's Liberation Army, Lanzhou, Gansu 730000, P.R. China.
Oncol Lett. 2019 Aug;18(2):1895-1903. doi: 10.3892/ol.2019.10523. Epub 2019 Jun 24.
Transcription factors (TFs) play key roles in biological processes, and previous studies revealed that they can control oncogenic processes. However, the functional impact of TFs on the prognosis of patients with cancer has not been extensively elucidated. In the context of The Cancer Genome Atlas, few studies have focused on the roles of TFs in tumorigenesis. In the present study, a TF-based robust MYC-estrogen related receptor α-regulatory factor X5 (MYC-ESRRA-RFX5) signature was developed for predicting the survival of patients with renal cell carcinoma. Functional enrichment analysis of this signature revealed that it was associated with the immune system of these patients. Further analysis demonstrated that this panel could characterize the immune microenvironment and potentially predicts the effectiveness of immune checkpoint inhibitors. Therefore, the present study recommends future exploration on TF-based biomarkers for their potential as prognostic predictors. Overall, the highlights of this study are: i) This novel study pinpoints a TF panel for the robust prediction of renal cell carcinoma prognosis, and ii) the MYC-ESRRA-RFX5 panel is proposed as a signature for characterizing the immune microenvironment, and to potentially predict the effectiveness of immune checkpoint inhibitors.
转录因子(TFs)在生物学过程中发挥着关键作用,先前的研究表明它们可以控制致癌过程。然而,TFs对癌症患者预后的功能影响尚未得到广泛阐明。在癌症基因组图谱的背景下,很少有研究关注TFs在肿瘤发生中的作用。在本研究中,开发了一种基于TF的稳健的MYC-雌激素相关受体α-调节因子X5(MYC-ESRRA-RFX5)特征,用于预测肾细胞癌患者的生存情况。对该特征的功能富集分析表明,它与这些患者的免疫系统有关。进一步分析表明,该指标可以表征免疫微环境,并有可能预测免疫检查点抑制剂的疗效。因此,本研究建议未来探索基于TF的生物标志物作为预后预测指标的潜力。总的来说,本研究的亮点在于:i)这项新研究确定了一个TF指标用于稳健预测肾细胞癌预后,ii)提出MYC-ESRRA-RFX5指标作为表征免疫微环境的特征,并有可能预测免疫检查点抑制剂的疗效。